Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 46,10 € (+82,00%). Mediana wynosi 47,31 € (+86,77%).
| Kupuj |
10 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Cogent Bioscience files FDA application for bezuclastinib to treat advanced systemic mastocytosis
Cogent Bioscience filed a New Drug Application with the U.S. FDA for bezuclastinib on June 30, supported by encouraging results from the APEX pivotal trial. CEO Andrew Robbins said the company is engaging closely with the FDA on three submissions and expects initial approvals by the end of 2026. The company is also advancing a JAK2 V617F mutation‑specific inhibitor with plans to file an IND in 2026. Bezuclastinib is a selective tyrosine kinase inhibitor targeting KIT mutations and is approaching Phase 3 development. » Więcej na finance.yahoo.com
Cogent Biosciences presents preclinical data showing mutant‑selective JAK2 inhibitor CGT1145 with >100‑fold selectivity
Cogent Biosciences reported early preclinical results for CGT1145 showing more than 100‑fold selectivity for JAK2 V617F over wild‑type JAK2 and JAK1/3, suggesting reduced off‑target effects that can cause low blood counts. The compound demonstrated strong oral bioavailability, consistent pharmacology across models, and potential to eradicate disease‑driving cells and support molecular remission in JAK2 V617F‑driven blood cancers. Cogent said it remains on track to file an Investigational New Drug application with the FDA later this year. » Więcej na finance.yahoo.com
Cogent Biosciences projects >$3bn peak sales for bezuclastinib amid near-term regulatory catalysts
Cogent Biosciences is advancing bezuclastinib, a selective KIT D816V inhibitor, with NDAs accepted for indolent systemic mastocytosis (PDUFA Dec 2026) and imminent submission for advanced disease, and an RTOR NDA for second-line GIST where trials showed improved PFS versus standard care. The company also develops additional oncology assets (pan-KRAS, JAK2, FGFR2/3) that broaden its commercial optionality. Analysts and investors view Cogent as an attractive M&A target given de-risked data, multiple near-term catalysts and projected multibillion-dollar sales, though safety and competition remain risks. » Więcej na finance.yahoo.com
Kynam Capital trims $48M position in Cogent Biosciences but leaves it as top holding
Kynam Capital Management sold 1,720,949 shares of Cogent Biosciences in Q4, an estimated $48.38 million reduction based on quarterly average pricing, while the position still represents about 14% of reported AUM and remains the fund's largest holding. Cogent shares have surged roughly 360% over the past year and trade at $33.38 as of Friday. Recent catalysts include FDA acceptance of bezuclastinib’s filing with a December 30 target action date and year-end cash of $900.8 million, supporting operations into 2028. The sale appears to be a risk-management trim rather than a shift in conviction according to the filing and portfolio context. » Więcej na finance.yahoo.com
Cogent Biosciences advances bezuclastinib NDAs after positive pivotal trials and secures strong cash runway
Cogent Biosciences reported 2025 regulatory momentum for lead candidate bezuclastinib following three positive pivotal trials and submitted an NDA for Non-Advanced Systemic Mastocytosis in December 2025, with an Advanced Systemic Mastocytosis NDA expected in H1 2026. The company is also completing a rolling NDA for second-line GIST under the FDA Real-Time Oncology Review, supported by PEAK trial data showing median progression-free survival of 16.5 months. Cogent maintains a robust pipeline including CGT1145 and CGT1815 and ended 2025 with $900.8 million in cash and marketable securities, funded partly by a $546.8 million offering and projected to finance operations into 2028. » Więcej na finance.yahoo.com
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | 0 | - |
| Zysk netto | -98,37 mln | 42,65% |
| EBITDA | -96,77 mln | 44,99% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 4,52 mld € |
Liczba akcji | 173,99 mln |
Maksimum/minimum z 52 tygodni | 39,79 € - 25,23 € |
| Dywidendy | Nie |
Beta | 0,34 |
C/Z (PE Ratio) | -12,31 |
PEG (PEG Ratio) | -2,02 |
C/WK (PB Ratio) | 9,58 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Cogent Biosciences, Inc., firma biotechnologiczna, koncentruje się na opracowywaniu precyzyjnych terapii chorób uwarunkowanych genetycznie. Jej wiodącym kandydatem na produkt jest CGT9486, selektywny inhibitor kinazy tyrozynowej zaprojektowany w celu hamowania mutacji KIT D816V, która napędza mastocytozę układową, a także innych mutacji w eksonie 17 genu KIT, występujących u pacjentów z zaawansowanymi nowotworami podścieliska przewodu pokarmowego (GIST). Firma ma umowę licencyjną z Plexxikon Inc. dotyczącą badań, rozwoju i komercjalizacji bezuklastynibu. Spółka była wcześniej znana jako Unum Therapeutics Inc. i zmieniła nazwę na Cogent Biosciences, Inc. w październiku 2020 roku. Cogent Biosciences, Inc. została założona w 2014 roku i ma siedzibę w Cambridge w stanie Massachusetts.
| Nazwa | COGENT BIOSC.INC.DL-,001 |
| CEO | Andrew R. Robbins |
| Siedziba | Waltham,
ma Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 29.03.2018 |
| Pracownicy | 258 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | COGT |